Published in Invest Radiol on October 01, 2010
Eu(II)-containing cryptates as contrast agents for ultra-high field strength magnetic resonance imaging. Chem Commun (Camb) (2011) 1.14
High-relaxivity magnetic resonance imaging contrast agents. Part 2. Optimization of inner- and second-sphere relaxivity. Invest Radiol (2010) 1.03
Gd(DOTAla): a single amino acid Gd-complex as a modular tool for high relaxivity MR contrast agent development. J Am Chem Soc (2012) 1.00
Contrast agents for MRI: 30+ years and where are we going? J Biol Inorg Chem (2014) 0.94
MR imaging probes: design and applications. Dalton Trans (2015) 0.93
Structure - relaxivity relationships among targeted MR contrast agents. Eur J Inorg Chem (2012) 0.91
Is macrocycle a synonym for kinetic inertness in Gd(III) Complexes? Effect of coordinating and noncoordinating substituents on inertness and relaxivity of Gd(III) chelates with DO3A-like ligands. Inorg Chem (2013) 0.89
Serum albumin targeted, pH-dependent magnetic resonance relaxation agents. Chemistry (2012) 0.85
25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives. Adv Ther (2016) 0.84
Structure-redox-relaxivity relationships for redox responsive manganese-based magnetic resonance imaging probes. Inorg Chem (2014) 0.84
Probing the structure-relaxivity relationship of bis-hydrated Gd(DOTAla) derivatives. Inorg Chem (2015) 0.78
Characterization of estrogen-receptor-targeted contrast agents in solution, breast cancer cells, and tumors in vivo. Magn Reson Med (2012) 0.78
[Gd(CyPic3A)(H2O)2]-: a stable, bis(aquated) and high-relaxivity Gd(III) complex. Chem Commun (Camb) (2013) 0.78
A new ditopic Gd(III) complex functionalized with an adamantyl moiety as a versatile building block for the preparation of supramolecular assemblies. J Biol Inorg Chem (2013) 0.77
Gd(DOTAlaP): exploring the boundaries of fast water exchange in gadolinium-based magnetic resonance imaging contrast agents. Inorg Chem (2014) 0.77
Facile synthesis of Gd-doped CdTe quantum dots with optimized properties for optical/MR multimodal imaging. J Biol Inorg Chem (2017) 0.77
MRI study of subconjunctival and intravitreal injections. J Pharm Sci (2012) 0.75
Bifunctional chelates optimized for molecular MRI. Inorg Chem (2014) 0.75
Gd3TCAS2: An Aquated Gd(3+)-Thiacalix[4]arene Sandwich Cluster with Extremely Slow Ligand Substitution Kinetics. Inorg Chem (2016) 0.75
Intramolecular Hydrogen Bonding Restricts Gd-Aqua-Ligand Dynamics. Angew Chem Int Ed Engl (2017) 0.75
Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. Chem Rev (1999) 12.52
In situ activation of bis-dialkylaminophosphines--a new method for synthesizing deoxyoligonucleotides on polymer supports. Nucleic Acids Res (1984) 4.55
Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev (2006) 4.27
Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents. Contrast Media Mol Imaging (2009) 2.48
The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc (2002) 2.28
Gadolinium and nephrogenic systemic fibrosis. Kidney Int (2007) 2.01
Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging (2006) 1.97
Bioresponsive, cell-penetrating, and multimeric MR contrast agents. Acc Chem Res (2009) 1.94
Pushing the sensitivity envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging applications. Acc Chem Res (2009) 1.86
pH-dependent modulation of relaxivity and luminescence in macrocyclic gadolinium and europium complexes based on reversible intramolecular sulfonamide ligation. J Am Chem Soc (2001) 1.74
Inorganic and bioinorganic solvent exchange mechanisms. Chem Rev (2005) 1.64
Towards the rational design of magnetic resonance imaging contrast agents: isolation of the two coordination isomers of lanthanide DOTA-type complexes. Angew Chem Int Ed Engl (2003) 1.62
Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg Chem (2007) 1.58
Potentiometric and relaxometric properties of a gadolinium-based MRI contrast agent for sensing tissue pH. Inorg Chem (2007) 1.44
High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol (2008) 1.38
Gd-hydroxypyridinone (HOPO)-based high-relaxivity magnetic resonance imaging (MRI) contrast agents. Acc Chem Res (2009) 1.35
Synthesis and evaluation of a high relaxivity manganese(II)-based MRI contrast agent. Inorg Chem (2004) 1.30
Synthesis and relaxometric studies of a dendrimer-based pH-responsive MRI contrast agent. Chemistry (2008) 1.28
Towards the rational design of MRI contrast agents: a practical approach to the synthesis of gadolinium complexes that exhibit optimal water exchange. Dalton Trans (2005) 1.27
The impact of rigidity and water exchange on the relaxivity of a dendritic MRI contrast agent. Chemistry (2002) 1.26
Synthesis, relaxometric and photophysical properties of a new pH-responsive MRI contrast agent: the effect of other ligating groups on dissociation of a p-nitrophenolic pendant arm. J Am Chem Soc (2004) 1.15
Protein binding to lanthanide(III) complexes can reduce the water exchange rate at the lanthanide. Inorg Chem (2007) 1.13
Ternary Gd(III)L-HSA adducts: evidence for the replacement of inner-sphere water molecules by coordinating groups of the protein. Implications for the design of contrast agents for MRI. J Biol Inorg Chem (2000) 1.09
Species dependence on plasma protein binding and relaxivity of the gadolinium-based MRI contrast agent MS-325. Invest Radiol (2006) 1.05
The effect of the amide substituent on the biodistribution and tolerance of lanthanide(III) DOTA-tetraamide derivatives. Invest Radiol (2008) 1.04
High-relaxivity magnetic resonance imaging contrast agents. Part 2. Optimization of inner- and second-sphere relaxivity. Invest Radiol (2010) 1.03
A high-frequency EPR study of frozen solutions of Gd(III) complexes: straightforward determination of the zero-field splitting parameters and simulation of the NMRD profiles. J Am Chem Soc (2006) 1.02
The effect of a phosphodiester linking group on albumin binding, blood half-life, and relaxivity of intravascular diethylenetriaminepentaacetato aquo gadolinium(III) MRI contrast agents. J Med Chem (2002) 1.00
Probing the water coordination of protein-targeted MRI contrast agents by pulsed ENDOR spectroscopy. Chemphyschem (2005) 0.99
Targeted relaxation enhancement agents for MRI. Magn Reson Med (1991) 0.98
The Gd(3+) complex of a fatty acid analogue of DOTP binds to multiple albumin sites with variable water relaxivities. Inorg Chem (2001) 0.97
Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. Invest Radiol (2010) 0.97
How does internal motion influence the relaxation of the water protons in Ln(III)DOTA-like complexes? J Am Chem Soc (2002) 0.96
The gadolinium(III)-water hydrogen distance in MRI contrast agents. Inorg Chem (2003) 0.96
Lanthanide(III) complexes of a mono(methylphosphonate) analogue of H4dota: the influence of protonation of the phosphonate moiety on the TSAP/SAP isomer ratio and the water exchange rate. Chemistry (2005) 0.94
Gadolinium(III) complexes of mono- and diethyl esters of monophosphonic acid analogue of DOTA as potential MRI contrast agents: solution structures and relaxometric studies. Dalton Trans (2006) 0.93
New multimeric magnetic resonance imaging agents. Invest Radiol (1998) 0.90
A simple, regioselective synthesis of 1,4-bis(tert-butoxycarbonylmethyl)- tetraazacyclododecane. J Org Chem (2003) 0.88
In vivo evaluation of a new magnetic resonance imaging contrast agent (P947) to target matrix metalloproteinases in expanding experimental abdominal aortic aneurysms. Invest Radiol (2010) 0.87
Determination of the hydration number of gadolinium(III) complexes by high-field pulsed 17O ENDOR spectroscopy. Chemphyschem (2006) 0.85
Nuclear spin relaxation in paramagnetic systems (S>/=1) under fast rotation conditions. J Magn Reson (2003) 0.82
MD simulations of acyclic and macrocyclic Gd3+-based MRI contrast agents: influence of the internal mobility on water proton relaxivity. Chemistry (2003) 0.82
Ultralong spin coherence time in isotopically engineered diamond. Nat Mater (2009) 4.70
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology (2014) 2.40
EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus. J Am Chem Soc (2008) 1.98
Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging (2009) 1.95
HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc Natl Acad Sci U S A (2013) 1.82
Collagen-targeted MRI contrast agent for molecular imaging of fibrosis. Angew Chem Int Ed Engl (2007) 1.75
Primer on gadolinium chemistry. J Magn Reson Imaging (2009) 1.63
Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility. Invest Radiol (2009) 1.60
Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg Chem (2007) 1.58
Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol (2008) 1.55
Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent. Radiology (2008) 1.48
Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. J Hepatol (2012) 1.45
Potentiometric and relaxometric properties of a gadolinium-based MRI contrast agent for sensing tissue pH. Inorg Chem (2007) 1.44
Bimodal MR-PET agent for quantitative pH imaging. Angew Chem Int Ed Engl (2010) 1.32
Tissue-specific MR contrast agents. Eur J Radiol (2003) 1.31
Synthesis and evaluation of a high relaxivity manganese(II)-based MRI contrast agent. Inorg Chem (2004) 1.30
Synthesis and relaxometric studies of a dendrimer-based pH-responsive MRI contrast agent. Chemistry (2008) 1.28
Specific PET imaging of xC- transporter activity using a ¹⁸F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism. Clin Cancer Res (2011) 1.27
The impact of rigidity and water exchange on the relaxivity of a dendritic MRI contrast agent. Chemistry (2002) 1.26
Molecular MRI of intracranial thrombus in a rat ischemic stroke model. Stroke (2010) 1.24
Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol Dis (2012) 1.23
Monovalent and bivalent fibrin-specific MRI contrast agents for detection of thrombus. Angew Chem Int Ed Engl (2008) 1.20
Multilocus binding increases the relaxivity of protein-bound MRI contrast agents. Angew Chem Int Ed Engl (2005) 1.18
Enzyme-Activated Gd(3+) Magnetic Resonance Imaging Contrast Agents with a Prominent Receptor-Induced Magnetization Enhancement We thank Dr. Shrikumar Nair for helpful discussions. Angew Chem Int Ed Engl (2001) 1.16
Bimodal thrombus imaging: simultaneous PET/MR imaging with a fibrin-targeted dual PET/MR probe--feasibility study in rat model. Radiology (2010) 1.15
Protein binding to lanthanide(III) complexes can reduce the water exchange rate at the lanthanide. Inorg Chem (2007) 1.13
Fibrin specific peptides derived by phage display: characterization of peptides and conjugates for imaging. Bioconjug Chem (2012) 1.12
The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum Mol Genet (2013) 1.09
Molecular MRI of collagen to diagnose and stage liver fibrosis. J Hepatol (2013) 1.08
Molecular MRI of acute necrosis with a novel DNA-binding gadolinium chelate: kinetics of cell death and clearance in infarcted myocardium. Circ Cardiovasc Imaging (2011) 1.07
Species dependence on plasma protein binding and relaxivity of the gadolinium-based MRI contrast agent MS-325. Invest Radiol (2006) 1.05
Redox-activated manganese-based MR contrast agent. J Am Chem Soc (2013) 1.05
A lysine walk to high relaxivity collagen-targeted MRI contrast agents. Chem Commun (Camb) (2008) 1.04
The effect of the amide substituent on the biodistribution and tolerance of lanthanide(III) DOTA-tetraamide derivatives. Invest Radiol (2008) 1.04
Pycup--a bifunctional, cage-like ligand for (64)Cu radiolabeling. Mol Pharm (2013) 1.03
High-relaxivity magnetic resonance imaging contrast agents. Part 2. Optimization of inner- and second-sphere relaxivity. Invest Radiol (2010) 1.03
Targeted probes for cardiovascular MRI. Future Med Chem (2010) 1.02
Molecular MRI of Thrombosis. Curr Cardiovasc Imaging Rep (2010) 1.00
Gd(DOTAla): a single amino acid Gd-complex as a modular tool for high relaxivity MR contrast agent development. J Am Chem Soc (2012) 1.00
Polymethylated DOTA ligands. 2. Synthesis of rigidified lanthanide chelates and studies on the effect of alkyl substitution on conformational mobility and relaxivity. Inorg Chem (2002) 1.00
The DcpS inhibitor RG3039 improves motor function in SMA mice. Hum Mol Genet (2013) 0.99
In vivo evaluation of gadolinium hydroxypyridonate chelates: initial experience as contrast media in magnetic resonance imaging. J Med Chem (2005) 0.99
Probing the water coordination of protein-targeted MRI contrast agents by pulsed ENDOR spectroscopy. Chemphyschem (2005) 0.99
Fibrin-targeted PET probes for the detection of thrombi. Mol Pharm (2013) 0.98
Sequence-selective DNA cleavage by a chimeric metallopeptide. J Am Chem Soc (2003) 0.97
Histone deacetylases 1 and 2 maintain S-phase chromatin and DNA replication fork progression. Epigenetics Chromatin (2013) 0.97
Molecular magnetic resonance imaging of myocardial perfusion with EP-3600, a collagen-specific contrast agent: initial feasibility study in a swine model. Circulation (2009) 0.97
Evidence for weak protein binding of commercial extracellular gadolinium contrast agents. Magn Reson Med (2010) 0.95
Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia. J Child Neurol (2012) 0.95
Contrast agents for MRI: 30+ years and where are we going? J Biol Inorg Chem (2014) 0.94
Gadolinium-binding helix-turn-helix peptides: DNA-dependent MRI contrast agents. Chem Commun (Camb) (2003) 0.93
Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. PLoS One (2013) 0.93
Heteroditopic binding of magnetic resonance contrast agents for increased relaxivity. Angew Chem Int Ed Engl (2011) 0.93
Preclinical characterization of a novel class of 18F-labeled PET tracers for amyloid-β. J Nucl Med (2012) 0.93
Narrow-band single-photon emission in the near infrared for quantum key distribution. Opt Express (2006) 0.91
Gadofosveset-enhanced magnetic resonance imaging of human carotid atherosclerotic plaques: a proof-of-concept study. Invest Radiol (2010) 0.90
Is macrocycle a synonym for kinetic inertness in Gd(III) Complexes? Effect of coordinating and noncoordinating substituents on inertness and relaxivity of Gd(III) chelates with DO3A-like ligands. Inorg Chem (2013) 0.89
Molecular imaging of fibrin in a breast cancer xenograft mouse model. Invest Radiol (2012) 0.88
Imaging apolipoprotein AI in vivo. NMR Biomed (2011) 0.88
Stimulated emission depletion microscopy resolves individual nitrogen vacancy centers in diamond nanocrystals. ACS Nano (2013) 0.87
Discrete bimodal probes for thrombus imaging. J Am Chem Soc (2012) 0.87
Single KTP nanocrystals as second-harmonic generation biolabels in cortical neurons. Nanoscale (2013) 0.87
Peptide optimization and conjugation strategies in the development of molecularly targeted magnetic resonance imaging contrast agents. Methods Mol Biol (2014) 0.86
Serum albumin targeted, pH-dependent magnetic resonance relaxation agents. Chemistry (2012) 0.85
Determination of the hydration number of gadolinium(III) complexes by high-field pulsed 17O ENDOR spectroscopy. Chemphyschem (2006) 0.85
Effect of Peptide-Chelate Architecture on Metabolic Stability of Peptide-based MRI Contrast Agents. New J Chem (2010) 0.85
Structure-redox-relaxivity relationships for redox responsive manganese-based magnetic resonance imaging probes. Inorg Chem (2014) 0.84
Structure-relaxivity relationships of serum albumin targeted MRI probes based on a single amino acid Gd complex. J Med Chem (2013) 0.84
Comparative studies on the efficacy of MRI contrast agents in MRA. Acad Radiol (2002) 0.83
Direct measurement of the Mn(II) hydration state in metal complexes and metalloproteins through 17O NMR line widths. J Am Chem Soc (2013) 0.82
On the philosophy of optimizing contrast agents. An analysis of 1H NMRD profiles and ESR lineshapes of the Gd(III)complex MS-325+HSA. J Magn Reson (2004) 0.82
Activation and retention: a magnetic resonance probe for the detection of acute thrombosis. Angew Chem Int Ed Engl (2013) 0.80
PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats. J Pharmacol Exp Ther (2010) 0.80
A gadolinium triacetic monoamide DOTA derivative with a methanethiosulfonate anchor group. Relaxivity properties and conjugation with albumin and thiolated particles. Contrast Media Mol Imaging (2007) 0.80
Auto-assembling of ditopic macrocyclic lanthanide chelates with transition-metal ions. Rigid multimetallic high relaxivity contrast agents for magnetic resonance imaging. Inorg Chem (2006) 0.79
Probing the structure-relaxivity relationship of bis-hydrated Gd(DOTAla) derivatives. Inorg Chem (2015) 0.78
[Gd(CyPic3A)(H2O)2]-: a stable, bis(aquated) and high-relaxivity Gd(III) complex. Chem Commun (Camb) (2013) 0.78
Europium luminescence of EF-hand helix-turn-helix chimeras: impact of pH and DNA-binding on europium coordination. Inorg Chem (2003) 0.78
Strategies for the preparation of bifunctional gadolinium(III) chelators. Curr Org Synth (2011) 0.78
Hexameric Mn(II) dendrimer as MRI contrast agent. Chemistry (2014) 0.78
Polymethylated DOTA ligands. 1. Synthesis of rigidified ligands and studies on the effects of alkyl substitution on acid-base properties and conformational mobility. Inorg Chem (2002) 0.78
1H chemical shift magnetic resonance imaging probes with high sensitivity for multiplex imaging. Contrast Media Mol Imaging (2012) 0.77
Interstitial magnetic resonance lymphography using a polymeric t1 contrast agent: initial experience with Gadomer-17. Invest Radiol (2002) 0.77
Magnetic resonance labeling of stem cells: is positive tracking a plus or a minus? JACC Cardiovasc Imaging (2009) 0.77
Molecular MRI of Atherosclerotic Plaque With Targeted Contrast Agents. Curr Cardiovasc Imaging Rep (2009) 0.77
Gd(DOTAlaP): exploring the boundaries of fast water exchange in gadolinium-based magnetic resonance imaging contrast agents. Inorg Chem (2014) 0.77
Structural, kinetic, and thermodynamic characterization of the interconverting isomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg Chem (2007) 0.76
Science to practice: how will myocardial inflammation be imaged with MR imaging? Radiology (2012) 0.75
Molecular MRI of the Cardiovascular System in the Post-NSF Era. Curr Cardiovasc Imaging Rep (2012) 0.75